Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rimonabant

Next Previous
Search
Drug Profile

Rimonabant

Alternative Names: Acomplia; SR 141716; SR 141716A; Zimulti

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Amides; Antihyperlipidaemics; Obesity therapies; Piperidines; Pyrazoles; Small molecules; Smoking cessation therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Obesity; Type 2 diabetes mellitus
  • Discontinued Atherosclerosis; Cardiovascular disorders; Cognition disorders; Hyperlipidaemia; Liver disorders; Neuropathic pain; Schizophrenia; Smoking withdrawal

Most Recent Events

  • 05 Dec 2008 Withdrawn for Obesity in European Union (PO)
  • 05 Dec 2008 Withdrawn for Type-2 diabetes mellitus in European Union (PO)
  • 05 Nov 2008 Discontinued - Phase-III for Atherosclerosis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top
pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy